Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA appropriations

This article was originally published in The Gray Sheet

Executive Summary

Senate approves FDA appropriations for fiscal 2010 on Aug. 4, including $315 million for the device center - approximately $35 million more than the center received in FY 2009. Overall, the Senate Agriculture Appropriations Act would give FDA about $2.35 billion in FY 2010, a $299 million increase over the prior year and the same amount approved by the House July 9 (1"The Gray Sheet" July 13, 2009)

You may also be interested in...

Capitol Hill Briefs

FDA approps: The House passes 2010 FDA appropriations July 9, including a $35 million increase for CDRH from last year to well over $300 million. The Agriculture Appropriations Act includes $2.35 billion in total appropriations for FDA, a $299 million bump from 2009, equaling the Obama administration's request (1"The Gray Sheet" June 15, 2009). The Senate Appropriations Committee approved the same funding on July 7, but it still needs to be voted on by the full Senate

Coronavirus Notebook: UK On Cusp Of First Vaccine Approval, Moderna To File mRNA-1273 in US & EU

Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.

Edgewell Finds COVID Bright Side: Wet Ones On Way To Becoming ‘Little Mega-Brand’

Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts